Page last updated: 2024-08-21

indazoles and thalidomide

indazoles has been researched along with thalidomide in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bayer, M; Berdel, WE; Kessler, T; Liersch, R; Mesters, RM; Schwöppe, C	1
Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES	1
Berry, L; Boe, M; Chesi, M; Del Rosario, G; Du, C; Ebens, A; Friedman, LS; Leif Bergsagel, P; Mariathasan, S; Munugalavadla, V; Slaga, D; Sun, L; Yan, Y	1
Campos-Rodriguez, C; Islas-Espinoza, AM; San Juan, ER	1

Reviews

2 review(s) available for indazoles and thalidomide

Article	Year
Compounds in clinical Phase III and beyond. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2010, Volume: 180 Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Clinical Trials, Phase III as Topic; Endostatins; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A	2010
Novel molecular targeted therapies for refractory thyroid cancer. Head & neck, 2012, Volume: 34, Issue:5 Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat	2012

Article

Year

Compounds in clinical Phase III and beyond.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2010, Volume: 180

Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Clinical Trials, Phase III as Topic; Endostatins; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A

2010

Novel molecular targeted therapies for refractory thyroid cancer.

Head & neck, 2012, Volume: 34, Issue:5

Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat

2012

Other Studies

2 other study(ies) available for indazoles and thalidomide

Article	Year
The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma. Oncogene, 2014, Jan-16, Volume: 33, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Cells, Cultured; Class I Phosphatidylinositol 3-Kinases; Dexamethasone; Female; Humans; Indazoles; Inhibitory Concentration 50; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Sulfonamides; Thalidomide; Tumor Burden; Xenograft Model Antitumor Assays	2014
Thalidomide protects against acute pentylenetetrazol and pilocarpine-induced seizures in mice. The Journal of toxicological sciences, 2018, Volume: 43, Issue:11 Topics: 4-Aminopyridine; Acute Disease; Animals; Anticonvulsants; Disease Models, Animal; Drug Therapy, Combination; Ibuprofen; Indazoles; Male; Mice, Inbred Strains; Neurotoxins; Nitric Oxide; Pentylenetetrazole; Pilocarpine; Seizures; Thalidomide	2018

Article

Year

The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.

Oncogene, 2014, Jan-16, Volume: 33, Issue:3

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Cells, Cultured; Class I Phosphatidylinositol 3-Kinases; Dexamethasone; Female; Humans; Indazoles; Inhibitory Concentration 50; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Sulfonamides; Thalidomide; Tumor Burden; Xenograft Model Antitumor Assays

2014

Thalidomide protects against acute pentylenetetrazol and pilocarpine-induced seizures in mice.

The Journal of toxicological sciences, 2018, Volume: 43, Issue:11

Topics: 4-Aminopyridine; Acute Disease; Animals; Anticonvulsants; Disease Models, Animal; Drug Therapy, Combination; Ibuprofen; Indazoles; Male; Mice, Inbred Strains; Neurotoxins; Nitric Oxide; Pentylenetetrazole; Pilocarpine; Seizures; Thalidomide

2018